RB Consumer Provides Bright Spot In Dim Quarter Despite Slower Sales
This article was originally published in The Tan Sheet
RB missed analysts third-quarter expectations by 1%, reporting a 2% sales increase to $3.82 billion. Consumer health product sales led the way with a 6% increase to $1.21 billion, dragged down slightly by slower than expected uptake of Mucinex and MegaRed products.
You may also be interested in...
Pfizer Likes Consumer, But Not U.S. Tax Policy; Consumer Segment Stays At Reckitt, Rx To Leave; Merck Consumer Brands Strong With Division Sale Pending; Exchange Rates Deflate Bayer Growth; No Buyer’s Remorse At Sanofi; and Gummy Vitamin Business Soars For C&D
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.